US Patent

US11413323 — Ophthalmic composition for treatment of dry eye disease

Method of Use · Assigned to Novaliq GmbH · Expires 2039-10-11 · 13y remaining

Vulnerability score 70/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects ophthalmic compositions containing cyclosporine dissolved in 1-(perfluorobutyl)pentane for treating dry eye disease.

USPTO Abstract

The invention provides ophthalmic compositions comprising about 0.1 % (w/v) cyclosporine dissolved in 1-(perfluorobutyl)pentane for use in the topical treatment of dry eye disease. The invention further provides kits comprising such compositions for the same use.

Drugs covered by this patent

Sandimmune (cyclosporine) · Novartis AG (originally Sandoz)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3627`	—	Sandimmune

Patent Metadata

Patent number: US11413323
Jurisdiction: US
Classification: Method of Use
Expires: 2039-10-11
Drug substance claim: No
Drug product claim: No
Assignee: Novaliq GmbH
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.